CN107708678A - 治疗乳房病症以及雌激素相关病症的组合物和方法 - Google Patents

治疗乳房病症以及雌激素相关病症的组合物和方法 Download PDF

Info

Publication number
CN107708678A
CN107708678A CN201680034873.1A CN201680034873A CN107708678A CN 107708678 A CN107708678 A CN 107708678A CN 201680034873 A CN201680034873 A CN 201680034873A CN 107708678 A CN107708678 A CN 107708678A
Authority
CN
China
Prior art keywords
breast
fatty acid
composition
vitamin
omega
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680034873.1A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文·C·夸伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atossa Therapeutics Inc
Original Assignee
Atossa Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atossa Genetics Inc filed Critical Atossa Genetics Inc
Publication of CN107708678A publication Critical patent/CN107708678A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201680034873.1A 2015-04-14 2016-04-06 治疗乳房病症以及雌激素相关病症的组合物和方法 Pending CN107708678A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562147536P 2015-04-14 2015-04-14
US62/147,536 2015-04-14
PCT/US2016/026170 WO2016168021A1 (en) 2015-04-14 2016-04-06 Compositions and methods of treatment of breast disorders and estrogen-related disorders

Publications (1)

Publication Number Publication Date
CN107708678A true CN107708678A (zh) 2018-02-16

Family

ID=57127000

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680034873.1A Pending CN107708678A (zh) 2015-04-14 2016-04-06 治疗乳房病症以及雌激素相关病症的组合物和方法

Country Status (7)

Country Link
US (1) US20180049999A1 (cg-RX-API-DMAC7.html)
EP (1) EP3283061A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018514511A (cg-RX-API-DMAC7.html)
CN (1) CN107708678A (cg-RX-API-DMAC7.html)
AU (1) AU2016247674A1 (cg-RX-API-DMAC7.html)
CA (1) CA2981301A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016168021A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113573706A (zh) * 2019-03-15 2021-10-29 洛利制药有限责任公司 用维生素d和表没食子儿茶素没食子酸酯(egcg)等药物治疗纤维瘤

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180169034A1 (en) * 2015-06-14 2018-06-21 Trs Ii, Llc Transdermal delivery formulation
CA2992282A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
CN110099680B (zh) 2016-10-11 2021-02-05 杜克大学 Er+乳腺癌的拉索昔芬治疗
CN111212635A (zh) * 2017-09-11 2020-05-29 阿托莎医疗公司 局部用组合物
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
TW201919594A (zh) * 2017-09-11 2019-06-01 美商艾陶莎基因有限公司 局部用組合物及治療方法
CA3094072A1 (en) * 2018-03-15 2019-09-19 Atossa Therapeutics, Inc. In situ methods of inducing of immune response
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
WO2019232485A1 (en) * 2018-05-31 2019-12-05 Nvigen, Inc. Accurate blood test to predict cancer incidence, recurrence, guide and monitor treatment intervention
US12390435B2 (en) 2018-11-14 2025-08-19 University of Pittsburgh—of the Commonwealth System of Higher Education Electrophiles and electrophile pro-drugs as RAD51 inhibitors
EP3980006A2 (en) * 2019-06-07 2022-04-13 Diomics Corporation Topical time release delivery using layered biopolymer
WO2021003433A1 (en) * 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
BR112022001165A2 (pt) * 2019-07-23 2022-05-17 Scherer Technologies Llc R P Formulações de cápsula de casca macia e métodos de preparação e uso das mesmas
US11915811B2 (en) * 2019-09-03 2024-02-27 Kaival Labs, Inc. System and method for determining an appropriate dose of a product
KR20220154196A (ko) * 2020-03-18 2022-11-21 알.피.쉐러 테크놀러지즈 엘엘씨 연질겔 캡슐
WO2021231904A1 (en) * 2020-05-14 2021-11-18 Diomics Corporation Detection and indication of covid-19, other viruses and pathogens and vaccine associated efficacy
CN111420046B (zh) * 2020-05-27 2021-01-12 四川省畜牧科学研究院 一种动物疫苗佐剂及其制备方法
WO2022187511A1 (en) * 2021-03-03 2022-09-09 Veramorph Llc Dissociating polymer matrix compositions of fulvestrant and methods of their making and use
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
KR102864596B1 (ko) * 2022-04-25 2025-09-26 유엠에스엔지니어링 주식회사 오메가 3 심리스 연질캡슐 제조방법
WO2025174794A1 (en) * 2024-02-12 2025-08-21 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20013336U1 (de) * 2000-08-02 2001-02-15 Bieger, Wilfried P., Priv.-Doz. Dr.med.habil., 80335 München Mund- und Zahnpflegegel
US20100092497A1 (en) * 2006-12-22 2010-04-15 Jagat Rakesh Kanwar Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
WO2014175748A1 (en) * 2013-04-22 2014-10-30 Smartfish As Use of a composition comprising fish oil and juice for the treatment and/or post treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149851A (en) * 1990-10-25 1992-09-22 The United States Of America As Represented By The Secretary Of Commerce Process for preparing triglycerides containing polyunsaturated fatty acid moieties
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE19738643C2 (de) * 1997-09-04 2001-10-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Scopolaminbase und Verfahren zu seiner Herstellung
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
WO2008113177A1 (en) * 2007-03-20 2008-09-25 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US20090068190A1 (en) * 2007-08-29 2009-03-12 Drugtech Corporation Anti-proliferative combinations
WO2014093313A1 (en) * 2012-12-10 2014-06-19 Jingxuan Kang Compositions and methods for integrated metabolic interventions
US8728546B1 (en) * 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
CN103734512A (zh) * 2013-12-20 2014-04-23 晓健科技(大连)有限公司 一种宠物猫补钙营养膏
CA2992282A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20013336U1 (de) * 2000-08-02 2001-02-15 Bieger, Wilfried P., Priv.-Doz. Dr.med.habil., 80335 München Mund- und Zahnpflegegel
US20100092497A1 (en) * 2006-12-22 2010-04-15 Jagat Rakesh Kanwar Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
WO2014175748A1 (en) * 2013-04-22 2014-10-30 Smartfish As Use of a composition comprising fish oil and juice for the treatment and/or post treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAY MING LEE ET AL.: ""In vitro delivery of anti-breast cancer agents directly via the mammary papilla(nipple)"", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113573706A (zh) * 2019-03-15 2021-10-29 洛利制药有限责任公司 用维生素d和表没食子儿茶素没食子酸酯(egcg)等药物治疗纤维瘤

Also Published As

Publication number Publication date
CA2981301A1 (en) 2016-10-20
EP3283061A4 (en) 2019-04-17
EP3283061A1 (en) 2018-02-21
JP2018514511A (ja) 2018-06-07
WO2016168021A1 (en) 2016-10-20
AU2016247674A1 (en) 2017-10-19
US20180049999A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
EP3283061A1 (en) Compositions and methods of treatment of breast disorders and estrogen-related disorders
RU2402331C2 (ru) Дроспиренон для гормональной заместительной терапии
JP2026035600A (ja) 送達増強エピネフリン組成物
Liu et al. Preparation and evaluation of glyceryl monooleate-coated hollow-bioadhesive microspheres for gastroretentive drug delivery
JP2005506367A (ja) 有効物質を徐放する3−(3−ジメチルアミノ−1−エチル−2−メチル−プロピル)フェノール含有医薬
TW201927304A (zh) 尼拉帕尼(niraparib)調配物
CN102413821A (zh) 经皮吸收型制剂
JP2016512833A (ja) ウイルス感染症の治療薬としてのベラプロスト異性体
JP2002080398A (ja) pHに依存する多相的な放出を伴う経口用の固体の薬学的組成物
JP2025087753A (ja) メトピマジンの新規多形形態
ES2273042T3 (es) Sistema mejorado de suministro transdermico.
US20180015074A1 (en) Use of mtor inhibitors to prevent and regress edhesions and fibrosis
TW201919608A (zh) 局部用組合物
KR20060127875A (ko) 아로마타제 억제제 요법-관련된 골다공증의 치료
WO2005007102A2 (en) Phytochemicals for the treatment of mastalgia, endometriosis and hpv-related conditions including cervical dysplasia
CN1223350C (zh) 用作避孕剂的炔雌醇和屈螺酮的药物联合形式
WO2021056109A1 (en) Gel base composition for compounding into a mucoadhesive delivery system
JP2020533342A (ja) 局所用組成物及び処置方法
CN116808226A (zh) 一种药物组合物及其制备方法和应用、含其的埋植剂
RU2346691C2 (ru) Применение 9-оксоакридин-10-уксусной кислоты и/или ее соли в комбинации с антиэстрогеном и/или прогестином для лечения эстрогензависимых опухолей, способ лечения и наборы
EP4736841A1 (en) A mucoadhesive layer for buccal administration of an active pharmaceutical ingredient
WO2025137145A1 (en) Oral formulations of (z)-endoxifen and methods of use thereof
JP2005528432A (ja) ノルエチンドロン徐放処方物およびそれに関連する方法
EP4734965A1 (en) Composition and method for pretreating cancer
HRP20020666A2 (en) Drospirenone for hormone replacement therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180216

WD01 Invention patent application deemed withdrawn after publication